InVivoPlus anti-mouse OX40 (CD134)
BP0031
ApplicationsWestern Blot, Other Application
Product group Antibodies
Overview
- SupplierBio X Cell
- Product NameInVivoPlus anti-mouse OX40 (CD134)
- Delivery Days Customer7
- ApplicationsWestern Blot, Other Application
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDOX-86
- Concentration4-11 mg/ml
- Estimated Purity>95%
- HostRat
- IsotypeIgG1
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Bartkowiak T, Singh S, Yang G, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015,112(38):E5290-9. doi: 10.1073/pnas.1514418112Read this paper
- Zander RA, Obeng-Adjei N, Guthmiller JJ, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015,17(5):628-41. doi: 10.1016/j.chom.2015.03.007Read this paper
- Makkouk A, Joshi VB, Lemke CD, et al. Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res. 2015,3(4):389-98. doi: 10.1158/2326-6066.CIR-14-0173Read this paper
- Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014,2(2):142-53. doi: 10.1158/2326-6066.CIR-13-0031-TRead this paper
- Guo Z, Wang X, Cheng D, et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One. 2014,9(2):e89350. doi: 10.1371/journal.pone.0089350Read this paper
- Krupnick AS, Lin X, Li W, et al. Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Invest. 2014,124(3):1130-43. doi: 10.1172/JCI71359Read this paper
- Hu Z, Zhang W, Usherwood EJ. Regulatory CD8+ T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect. J Immunol. 2013,191(1):312-22. doi: 10.4049/jimmunol.1201773Read this paper
- Kurche JS, Haluszczak C, McWilliams JA, et al. Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. J Immunol. 2012,188(2):585-93. doi: 10.4049/jimmunol.1102550Read this paper
- Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012,188(2):892-901. doi: 10.4049/jimmunol.1101373Read this paper
- Murray SE, Polesso F, Rowe AM, et al. NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J Clin Invest. 2011,121(12):4775-86. doi: 10.1172/JCI44943Read this paper
